nodes	percent_of_prediction	percent_of_DWPC	metapath
Nevirapine—CYP2A6—Progesterone—uterine cancer	0.174	0.226	CbGbCtD
Nevirapine—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0903	0.117	CbGbCtD
Nevirapine—CYP3A5—Progesterone—uterine cancer	0.0892	0.116	CbGbCtD
Nevirapine—CYP1A2—Progesterone—uterine cancer	0.0664	0.0864	CbGbCtD
Nevirapine—CYP2C9—Progesterone—uterine cancer	0.0598	0.0778	CbGbCtD
Nevirapine—CYP2D6—Progesterone—uterine cancer	0.0547	0.0712	CbGbCtD
Nevirapine—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0525	0.0683	CbGbCtD
Nevirapine—CYP3A5—Etoposide—uterine cancer	0.0399	0.0519	CbGbCtD
Nevirapine—CYP3A4—Progesterone—uterine cancer	0.0348	0.0452	CbGbCtD
Nevirapine—CYP2B6—Doxorubicin—uterine cancer	0.0346	0.045	CbGbCtD
Nevirapine—CYP1A2—Etoposide—uterine cancer	0.0297	0.0386	CbGbCtD
Nevirapine—CYP2D6—Doxorubicin—uterine cancer	0.0167	0.0217	CbGbCtD
Nevirapine—CYP3A4—Etoposide—uterine cancer	0.0156	0.0202	CbGbCtD
Nevirapine—CYP3A4—Doxorubicin—uterine cancer	0.0106	0.0138	CbGbCtD
Nevirapine—Anorexia—Progesterone—uterine cancer	0.000628	0.00272	CcSEcCtD
Nevirapine—Necrosis—Doxorubicin—uterine cancer	0.000625	0.0027	CcSEcCtD
Nevirapine—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	0.000623	0.0027	CcSEcCtD
Nevirapine—Myalgia—Medroxyprogesterone Acetate—uterine cancer	0.000623	0.0027	CcSEcCtD
Nevirapine—Erythema multiforme—Dactinomycin—uterine cancer	0.00062	0.00268	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.000619	0.00268	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Etoposide—uterine cancer	0.000618	0.00267	CcSEcCtD
Nevirapine—Discomfort—Medroxyprogesterone Acetate—uterine cancer	0.000616	0.00266	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Etoposide—uterine cancer	0.000605	0.00262	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Progesterone—uterine cancer	0.000601	0.0026	CcSEcCtD
Nevirapine—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.000597	0.00258	CcSEcCtD
Nevirapine—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.000597	0.00258	CcSEcCtD
Nevirapine—Paraesthesia—Progesterone—uterine cancer	0.000592	0.00256	CcSEcCtD
Nevirapine—Bone disorder—Epirubicin—uterine cancer	0.000587	0.00254	CcSEcCtD
Nevirapine—Somnolence—Progesterone—uterine cancer	0.000586	0.00253	CcSEcCtD
Nevirapine—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000586	0.00253	CcSEcCtD
Nevirapine—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.000585	0.00253	CcSEcCtD
Nevirapine—Liver injury—Doxorubicin—uterine cancer	0.000583	0.00252	CcSEcCtD
Nevirapine—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00058	0.00251	CcSEcCtD
Nevirapine—Decreased appetite—Progesterone—uterine cancer	0.000573	0.00248	CcSEcCtD
Nevirapine—Erythema—Dactinomycin—uterine cancer	0.000571	0.00247	CcSEcCtD
Nevirapine—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.000569	0.00246	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Progesterone—uterine cancer	0.000569	0.00246	CcSEcCtD
Nevirapine—Fatigue—Progesterone—uterine cancer	0.000568	0.00246	CcSEcCtD
Nevirapine—Pain—Progesterone—uterine cancer	0.000564	0.00244	CcSEcCtD
Nevirapine—Ulcer—Epirubicin—uterine cancer	0.00056	0.00242	CcSEcCtD
Nevirapine—Neutropenia—Etoposide—uterine cancer	0.000555	0.0024	CcSEcCtD
Nevirapine—Inflammation—Epirubicin—uterine cancer	0.000546	0.00236	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.000544	0.00235	CcSEcCtD
Nevirapine—Feeling abnormal—Progesterone—uterine cancer	0.000543	0.00235	CcSEcCtD
Nevirapine—Bone disorder—Doxorubicin—uterine cancer	0.000543	0.00235	CcSEcCtD
Nevirapine—Gastrointestinal pain—Progesterone—uterine cancer	0.000539	0.00233	CcSEcCtD
Nevirapine—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.000536	0.00232	CcSEcCtD
Nevirapine—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.000531	0.0023	CcSEcCtD
Nevirapine—Hepatocellular injury—Epirubicin—uterine cancer	0.00053	0.00229	CcSEcCtD
Nevirapine—Ill-defined disorder—Dactinomycin—uterine cancer	0.00053	0.00229	CcSEcCtD
Nevirapine—Anaemia—Dactinomycin—uterine cancer	0.000528	0.00228	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Etoposide—uterine cancer	0.000524	0.00227	CcSEcCtD
Nevirapine—Urticaria—Progesterone—uterine cancer	0.000524	0.00227	CcSEcCtD
Nevirapine—Body temperature increased—Progesterone—uterine cancer	0.000521	0.00225	CcSEcCtD
Nevirapine—Abdominal pain—Progesterone—uterine cancer	0.000521	0.00225	CcSEcCtD
Nevirapine—Renal failure—Etoposide—uterine cancer	0.00052	0.00225	CcSEcCtD
Nevirapine—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000519	0.00225	CcSEcCtD
Nevirapine—Ulcer—Doxorubicin—uterine cancer	0.000518	0.00224	CcSEcCtD
Nevirapine—Neuropathy peripheral—Etoposide—uterine cancer	0.000518	0.00224	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000516	0.00223	CcSEcCtD
Nevirapine—Jaundice—Etoposide—uterine cancer	0.000515	0.00223	CcSEcCtD
Nevirapine—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000515	0.00223	CcSEcCtD
Nevirapine—Malaise—Dactinomycin—uterine cancer	0.000515	0.00223	CcSEcCtD
Nevirapine—Skin exfoliation—Epirubicin—uterine cancer	0.000506	0.00219	CcSEcCtD
Nevirapine—Inflammation—Doxorubicin—uterine cancer	0.000505	0.00219	CcSEcCtD
Nevirapine—Hepatobiliary disease—Etoposide—uterine cancer	0.0005	0.00216	CcSEcCtD
Nevirapine—Agranulocytosis—Etoposide—uterine cancer	0.000493	0.00213	CcSEcCtD
Nevirapine—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.000492	0.00213	CcSEcCtD
Nevirapine—Hepatocellular injury—Doxorubicin—uterine cancer	0.00049	0.00212	CcSEcCtD
Nevirapine—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000489	0.00211	CcSEcCtD
Nevirapine—Myalgia—Dactinomycin—uterine cancer	0.000486	0.0021	CcSEcCtD
Nevirapine—Hypersensitivity—Progesterone—uterine cancer	0.000486	0.0021	CcSEcCtD
Nevirapine—Rash maculo-papular—Epirubicin—uterine cancer	0.000482	0.00208	CcSEcCtD
Nevirapine—Discomfort—Dactinomycin—uterine cancer	0.00048	0.00208	CcSEcCtD
Nevirapine—Mouth ulceration—Epirubicin—uterine cancer	0.000479	0.00207	CcSEcCtD
Nevirapine—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000475	0.00205	CcSEcCtD
Nevirapine—Asthenia—Progesterone—uterine cancer	0.000473	0.00205	CcSEcCtD
Nevirapine—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000472	0.00204	CcSEcCtD
Nevirapine—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000472	0.00204	CcSEcCtD
Nevirapine—Skin exfoliation—Doxorubicin—uterine cancer	0.000468	0.00202	CcSEcCtD
Nevirapine—Pruritus—Progesterone—uterine cancer	0.000466	0.00202	CcSEcCtD
Nevirapine—Oedema—Dactinomycin—uterine cancer	0.000466	0.00202	CcSEcCtD
Nevirapine—Thrombocytopenia—Dactinomycin—uterine cancer	0.000456	0.00197	CcSEcCtD
Nevirapine—Diarrhoea—Progesterone—uterine cancer	0.000451	0.00195	CcSEcCtD
Nevirapine—Lymphadenopathy—Epirubicin—uterine cancer	0.000451	0.00195	CcSEcCtD
Nevirapine—Erythema multiforme—Etoposide—uterine cancer	0.000449	0.00194	CcSEcCtD
Nevirapine—Rash maculo-papular—Doxorubicin—uterine cancer	0.000446	0.00193	CcSEcCtD
Nevirapine—Anorexia—Dactinomycin—uterine cancer	0.000444	0.00192	CcSEcCtD
Nevirapine—Mouth ulceration—Doxorubicin—uterine cancer	0.000443	0.00192	CcSEcCtD
Nevirapine—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.00044	0.0019	CcSEcCtD
Nevirapine—Immune system disorder—Etoposide—uterine cancer	0.000429	0.00185	CcSEcCtD
Nevirapine—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000429	0.00185	CcSEcCtD
Nevirapine—Hepatic failure—Epirubicin—uterine cancer	0.000428	0.00185	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000425	0.00184	CcSEcCtD
Nevirapine—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000423	0.00183	CcSEcCtD
Nevirapine—Vomiting—Progesterone—uterine cancer	0.000419	0.00181	CcSEcCtD
Nevirapine—Lymphadenopathy—Doxorubicin—uterine cancer	0.000417	0.0018	CcSEcCtD
Nevirapine—Rash—Progesterone—uterine cancer	0.000416	0.0018	CcSEcCtD
Nevirapine—Dermatitis—Progesterone—uterine cancer	0.000415	0.0018	CcSEcCtD
Nevirapine—Headache—Progesterone—uterine cancer	0.000413	0.00179	CcSEcCtD
Nevirapine—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000409	0.00177	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Epirubicin—uterine cancer	0.000408	0.00176	CcSEcCtD
Nevirapine—Decreased appetite—Dactinomycin—uterine cancer	0.000405	0.00175	CcSEcCtD
Nevirapine—Dermatitis bullous—Epirubicin—uterine cancer	0.000402	0.00174	CcSEcCtD
Nevirapine—Fatigue—Dactinomycin—uterine cancer	0.000402	0.00174	CcSEcCtD
Nevirapine—Pain—Dactinomycin—uterine cancer	0.000398	0.00172	CcSEcCtD
Nevirapine—Hepatic failure—Doxorubicin—uterine cancer	0.000396	0.00171	CcSEcCtD
Nevirapine—Nausea—Progesterone—uterine cancer	0.000392	0.00169	CcSEcCtD
Nevirapine—Feeling abnormal—Dactinomycin—uterine cancer	0.000384	0.00166	CcSEcCtD
Nevirapine—Ill-defined disorder—Etoposide—uterine cancer	0.000383	0.00166	CcSEcCtD
Nevirapine—Anaemia—Etoposide—uterine cancer	0.000382	0.00165	CcSEcCtD
Nevirapine—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000381	0.00165	CcSEcCtD
Nevirapine—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00038	0.00164	CcSEcCtD
Nevirapine—Dermatitis exfoliative—Doxorubicin—uterine cancer	0.000377	0.00163	CcSEcCtD
Nevirapine—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000377	0.00163	CcSEcCtD
Nevirapine—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000376	0.00163	CcSEcCtD
Nevirapine—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000374	0.00162	CcSEcCtD
Nevirapine—Malaise—Etoposide—uterine cancer	0.000373	0.00161	CcSEcCtD
Nevirapine—Dermatitis bullous—Doxorubicin—uterine cancer	0.000372	0.00161	CcSEcCtD
Nevirapine—Face oedema—Epirubicin—uterine cancer	0.000371	0.00161	CcSEcCtD
Nevirapine—Abdominal pain—Dactinomycin—uterine cancer	0.000368	0.00159	CcSEcCtD
Nevirapine—Body temperature increased—Dactinomycin—uterine cancer	0.000368	0.00159	CcSEcCtD
Nevirapine—Liver function test abnormal—Epirubicin—uterine cancer	0.000355	0.00154	CcSEcCtD
Nevirapine—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000355	0.00153	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000349	0.00151	CcSEcCtD
Nevirapine—Discomfort—Etoposide—uterine cancer	0.000348	0.0015	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000346	0.0015	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000346	0.0015	CcSEcCtD
Nevirapine—Face oedema—Doxorubicin—uterine cancer	0.000344	0.00149	CcSEcCtD
Nevirapine—Hypersensitivity—Dactinomycin—uterine cancer	0.000343	0.00148	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000339	0.00147	CcSEcCtD
Nevirapine—Anaphylactic shock—Etoposide—uterine cancer	0.000337	0.00146	CcSEcCtD
Nevirapine—Asthenia—Dactinomycin—uterine cancer	0.000334	0.00145	CcSEcCtD
Nevirapine—Thrombocytopenia—Etoposide—uterine cancer	0.00033	0.00143	CcSEcCtD
Nevirapine—Eosinophilia—Epirubicin—uterine cancer	0.000329	0.00142	CcSEcCtD
Nevirapine—Liver function test abnormal—Doxorubicin—uterine cancer	0.000329	0.00142	CcSEcCtD
Nevirapine—Skin disorder—Etoposide—uterine cancer	0.000328	0.00142	CcSEcCtD
Nevirapine—Pancreatitis—Epirubicin—uterine cancer	0.000326	0.00141	CcSEcCtD
Nevirapine—Anorexia—Etoposide—uterine cancer	0.000321	0.00139	CcSEcCtD
Nevirapine—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.00032	0.00139	CcSEcCtD
Nevirapine—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.00032	0.00139	CcSEcCtD
Nevirapine—Diarrhoea—Dactinomycin—uterine cancer	0.000319	0.00138	CcSEcCtD
Nevirapine—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000314	0.00136	CcSEcCtD
Nevirapine—Neutropenia—Epirubicin—uterine cancer	0.000311	0.00134	CcSEcCtD
Nevirapine—Eosinophilia—Doxorubicin—uterine cancer	0.000305	0.00132	CcSEcCtD
Nevirapine—Paraesthesia—Etoposide—uterine cancer	0.000303	0.00131	CcSEcCtD
Nevirapine—Pancreatitis—Doxorubicin—uterine cancer	0.000302	0.0013	CcSEcCtD
Nevirapine—Hyperglycaemia—Epirubicin—uterine cancer	0.0003	0.0013	CcSEcCtD
Nevirapine—Somnolence—Etoposide—uterine cancer	0.0003	0.0013	CcSEcCtD
Nevirapine—Vomiting—Dactinomycin—uterine cancer	0.000296	0.00128	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000294	0.00127	CcSEcCtD
Nevirapine—Rash—Dactinomycin—uterine cancer	0.000294	0.00127	CcSEcCtD
Nevirapine—Decreased appetite—Etoposide—uterine cancer	0.000293	0.00127	CcSEcCtD
Nevirapine—Renal failure—Epirubicin—uterine cancer	0.000291	0.00126	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Etoposide—uterine cancer	0.000291	0.00126	CcSEcCtD
Nevirapine—Fatigue—Etoposide—uterine cancer	0.000291	0.00126	CcSEcCtD
Nevirapine—Neuropathy peripheral—Epirubicin—uterine cancer	0.000291	0.00126	CcSEcCtD
Nevirapine—Jaundice—Epirubicin—uterine cancer	0.000289	0.00125	CcSEcCtD
Nevirapine—Pain—Etoposide—uterine cancer	0.000288	0.00125	CcSEcCtD
Nevirapine—Conjunctivitis—Epirubicin—uterine cancer	0.000288	0.00125	CcSEcCtD
Nevirapine—Neutropenia—Doxorubicin—uterine cancer	0.000288	0.00124	CcSEcCtD
Nevirapine—Hepatobiliary disease—Epirubicin—uterine cancer	0.00028	0.00121	CcSEcCtD
Nevirapine—Feeling abnormal—Etoposide—uterine cancer	0.000278	0.0012	CcSEcCtD
Nevirapine—Hyperglycaemia—Doxorubicin—uterine cancer	0.000277	0.0012	CcSEcCtD
Nevirapine—Nausea—Dactinomycin—uterine cancer	0.000277	0.0012	CcSEcCtD
Nevirapine—Agranulocytosis—Epirubicin—uterine cancer	0.000277	0.0012	CcSEcCtD
Nevirapine—Gastrointestinal pain—Etoposide—uterine cancer	0.000276	0.00119	CcSEcCtD
Nevirapine—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000272	0.00118	CcSEcCtD
Nevirapine—Renal failure—Doxorubicin—uterine cancer	0.00027	0.00117	CcSEcCtD
Nevirapine—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000269	0.00116	CcSEcCtD
Nevirapine—Urticaria—Etoposide—uterine cancer	0.000268	0.00116	CcSEcCtD
Nevirapine—Jaundice—Doxorubicin—uterine cancer	0.000267	0.00116	CcSEcCtD
Nevirapine—Abdominal pain—Etoposide—uterine cancer	0.000267	0.00115	CcSEcCtD
Nevirapine—Body temperature increased—Etoposide—uterine cancer	0.000267	0.00115	CcSEcCtD
Nevirapine—Conjunctivitis—Doxorubicin—uterine cancer	0.000267	0.00115	CcSEcCtD
Nevirapine—Hepatitis—Epirubicin—uterine cancer	0.000266	0.00115	CcSEcCtD
Nevirapine—Connective tissue disorder—Epirubicin—uterine cancer	0.000261	0.00113	CcSEcCtD
Nevirapine—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000259	0.00112	CcSEcCtD
Nevirapine—Agranulocytosis—Doxorubicin—uterine cancer	0.000256	0.00111	CcSEcCtD
Nevirapine—Erythema multiforme—Epirubicin—uterine cancer	0.000252	0.00109	CcSEcCtD
Nevirapine—Hypersensitivity—Etoposide—uterine cancer	0.000248	0.00107	CcSEcCtD
Nevirapine—Hepatitis—Doxorubicin—uterine cancer	0.000246	0.00106	CcSEcCtD
Nevirapine—Asthenia—Etoposide—uterine cancer	0.000242	0.00105	CcSEcCtD
Nevirapine—Connective tissue disorder—Doxorubicin—uterine cancer	0.000242	0.00105	CcSEcCtD
Nevirapine—Immune system disorder—Epirubicin—uterine cancer	0.00024	0.00104	CcSEcCtD
Nevirapine—Pruritus—Etoposide—uterine cancer	0.000239	0.00103	CcSEcCtD
Nevirapine—Erythema multiforme—Doxorubicin—uterine cancer	0.000233	0.00101	CcSEcCtD
Nevirapine—Erythema—Epirubicin—uterine cancer	0.000232	0.001	CcSEcCtD
Nevirapine—Diarrhoea—Etoposide—uterine cancer	0.000231	0.000998	CcSEcCtD
Nevirapine—Immune system disorder—Doxorubicin—uterine cancer	0.000222	0.000962	CcSEcCtD
Nevirapine—Ill-defined disorder—Epirubicin—uterine cancer	0.000215	0.00093	CcSEcCtD
Nevirapine—Vomiting—Etoposide—uterine cancer	0.000214	0.000927	CcSEcCtD
Nevirapine—Erythema—Doxorubicin—uterine cancer	0.000214	0.000927	CcSEcCtD
Nevirapine—Anaemia—Epirubicin—uterine cancer	0.000214	0.000926	CcSEcCtD
Nevirapine—Rash—Etoposide—uterine cancer	0.000213	0.00092	CcSEcCtD
Nevirapine—Dermatitis—Etoposide—uterine cancer	0.000212	0.000919	CcSEcCtD
Nevirapine—Headache—Etoposide—uterine cancer	0.000211	0.000914	CcSEcCtD
Nevirapine—Malaise—Epirubicin—uterine cancer	0.000209	0.000903	CcSEcCtD
Nevirapine—Nausea—Etoposide—uterine cancer	0.0002	0.000866	CcSEcCtD
Nevirapine—Ill-defined disorder—Doxorubicin—uterine cancer	0.000199	0.00086	CcSEcCtD
Nevirapine—Anaemia—Doxorubicin—uterine cancer	0.000198	0.000857	CcSEcCtD
Nevirapine—Myalgia—Epirubicin—uterine cancer	0.000197	0.000853	CcSEcCtD
Nevirapine—Arthralgia—Epirubicin—uterine cancer	0.000197	0.000853	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000196	0.000847	CcSEcCtD
Nevirapine—Discomfort—Epirubicin—uterine cancer	0.000195	0.000843	CcSEcCtD
Nevirapine—Malaise—Doxorubicin—uterine cancer	0.000193	0.000836	CcSEcCtD
Nevirapine—Oedema—Epirubicin—uterine cancer	0.000189	0.000818	CcSEcCtD
Nevirapine—Anaphylactic shock—Epirubicin—uterine cancer	0.000189	0.000818	CcSEcCtD
Nevirapine—Nervous system disorder—Epirubicin—uterine cancer	0.000185	0.000802	CcSEcCtD
Nevirapine—Thrombocytopenia—Epirubicin—uterine cancer	0.000185	0.000801	CcSEcCtD
Nevirapine—Skin disorder—Epirubicin—uterine cancer	0.000184	0.000794	CcSEcCtD
Nevirapine—Arthralgia—Doxorubicin—uterine cancer	0.000182	0.000789	CcSEcCtD
Nevirapine—Myalgia—Doxorubicin—uterine cancer	0.000182	0.000789	CcSEcCtD
Nevirapine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000181	0.000784	CcSEcCtD
Nevirapine—Discomfort—Doxorubicin—uterine cancer	0.00018	0.00078	CcSEcCtD
Nevirapine—Anorexia—Epirubicin—uterine cancer	0.00018	0.000779	CcSEcCtD
Nevirapine—Oedema—Doxorubicin—uterine cancer	0.000175	0.000757	CcSEcCtD
Nevirapine—Anaphylactic shock—Doxorubicin—uterine cancer	0.000175	0.000757	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000172	0.000745	CcSEcCtD
Nevirapine—Nervous system disorder—Doxorubicin—uterine cancer	0.000172	0.000742	CcSEcCtD
Nevirapine—Thrombocytopenia—Doxorubicin—uterine cancer	0.000171	0.000741	CcSEcCtD
Nevirapine—Skin disorder—Doxorubicin—uterine cancer	0.00017	0.000735	CcSEcCtD
Nevirapine—Paraesthesia—Epirubicin—uterine cancer	0.00017	0.000734	CcSEcCtD
Nevirapine—Somnolence—Epirubicin—uterine cancer	0.000168	0.000727	CcSEcCtD
Nevirapine—Anorexia—Doxorubicin—uterine cancer	0.000167	0.000721	CcSEcCtD
Nevirapine—Decreased appetite—Epirubicin—uterine cancer	0.000164	0.000711	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000163	0.000706	CcSEcCtD
Nevirapine—Fatigue—Epirubicin—uterine cancer	0.000163	0.000705	CcSEcCtD
Nevirapine—Pain—Epirubicin—uterine cancer	0.000162	0.000699	CcSEcCtD
Nevirapine—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000159	0.000689	CcSEcCtD
Nevirapine—Paraesthesia—Doxorubicin—uterine cancer	0.000157	0.000679	CcSEcCtD
Nevirapine—Feeling abnormal—Epirubicin—uterine cancer	0.000156	0.000674	CcSEcCtD
Nevirapine—Somnolence—Doxorubicin—uterine cancer	0.000156	0.000673	CcSEcCtD
Nevirapine—Gastrointestinal pain—Epirubicin—uterine cancer	0.000155	0.000669	CcSEcCtD
Nevirapine—Decreased appetite—Doxorubicin—uterine cancer	0.000152	0.000658	CcSEcCtD
Nevirapine—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000151	0.000653	CcSEcCtD
Nevirapine—Fatigue—Doxorubicin—uterine cancer	0.000151	0.000652	CcSEcCtD
Nevirapine—Urticaria—Epirubicin—uterine cancer	0.00015	0.00065	CcSEcCtD
Nevirapine—Pain—Doxorubicin—uterine cancer	0.00015	0.000647	CcSEcCtD
Nevirapine—Abdominal pain—Epirubicin—uterine cancer	0.000149	0.000646	CcSEcCtD
Nevirapine—Body temperature increased—Epirubicin—uterine cancer	0.000149	0.000646	CcSEcCtD
Nevirapine—Feeling abnormal—Doxorubicin—uterine cancer	0.000144	0.000623	CcSEcCtD
Nevirapine—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000143	0.000619	CcSEcCtD
Nevirapine—Hypersensitivity—Epirubicin—uterine cancer	0.000139	0.000602	CcSEcCtD
Nevirapine—Urticaria—Doxorubicin—uterine cancer	0.000139	0.000601	CcSEcCtD
Nevirapine—Abdominal pain—Doxorubicin—uterine cancer	0.000138	0.000598	CcSEcCtD
Nevirapine—Body temperature increased—Doxorubicin—uterine cancer	0.000138	0.000598	CcSEcCtD
Nevirapine—Asthenia—Epirubicin—uterine cancer	0.000136	0.000587	CcSEcCtD
Nevirapine—Pruritus—Epirubicin—uterine cancer	0.000134	0.000578	CcSEcCtD
Nevirapine—Diarrhoea—Epirubicin—uterine cancer	0.000129	0.000559	CcSEcCtD
Nevirapine—Hypersensitivity—Doxorubicin—uterine cancer	0.000129	0.000557	CcSEcCtD
Nevirapine—Asthenia—Doxorubicin—uterine cancer	0.000126	0.000543	CcSEcCtD
Nevirapine—Pruritus—Doxorubicin—uterine cancer	0.000124	0.000535	CcSEcCtD
Nevirapine—Vomiting—Epirubicin—uterine cancer	0.00012	0.00052	CcSEcCtD
Nevirapine—Diarrhoea—Doxorubicin—uterine cancer	0.00012	0.000518	CcSEcCtD
Nevirapine—Rash—Epirubicin—uterine cancer	0.000119	0.000516	CcSEcCtD
Nevirapine—Dermatitis—Epirubicin—uterine cancer	0.000119	0.000515	CcSEcCtD
Nevirapine—Headache—Epirubicin—uterine cancer	0.000118	0.000512	CcSEcCtD
Nevirapine—Nausea—Epirubicin—uterine cancer	0.000112	0.000486	CcSEcCtD
Nevirapine—Vomiting—Doxorubicin—uterine cancer	0.000111	0.000481	CcSEcCtD
Nevirapine—Rash—Doxorubicin—uterine cancer	0.00011	0.000477	CcSEcCtD
Nevirapine—Dermatitis—Doxorubicin—uterine cancer	0.00011	0.000477	CcSEcCtD
Nevirapine—Headache—Doxorubicin—uterine cancer	0.00011	0.000474	CcSEcCtD
Nevirapine—Nausea—Doxorubicin—uterine cancer	0.000104	0.000449	CcSEcCtD
